Filing Flows › Aligos Therapeutics (ALGS) › Guidance & outlook

Aligos Therapeutics (ALGS) guidance and outlook

Aligos Therapeutics' 10-Q filed Nov 6, 2026 makes 13 forward-looking statements.

Guidance and outlook

Forward-looking statements, 10-Q filed Nov 6, 2026

• We expect our research and development expenses to increase substantially in connection with our ongoing and planned clinical development activities for pevifoscorvir sodium and our other drug candidates.
• As a result, we are unable to determine the duration and completion costs of our research and development projects or clinical trials or if and to what extent we will generate revenue from the commercialization and sale of any of our drug candidates.
• We expect research and development expenses will increase in future periods as we continue to focus on advancing clinical trials for pevifoscorvir sodium.
• We expect general and administrative expenses will increase in future periods due to increased activity in our research and development group, which will require more resources and additional activities in our general and administration group.
• We expect to continue to incur significant expenses and increasing operating losses over at least the next several years.
• Our current operating plan and projected cash outflows for the upcoming periods raise substantial doubt about our ability to continue as a going concern for at least 12 months from the issuance of the financial statements included elsewhere in this Quarterly Report.
• We plan to raise additional capital to fund continued operations beyond the first quarter of 2027.
• We are taking steps to identify access to future capital and expect to be able to access capital in the future.
• However, there can be no assurance that any additional funding will be available to us on acceptable terms, if at all.
• If we are successful with our ability to access additional funding, we expect our expenses to increase substantially in connection with our ongoing clinical development activities related to our chronic HBV infection drug candidate pevifoscorvir sodium, for which we have an ongoing Phase 2 trial, as well as our research and development of our other drug candidates.
• We expect that our expenses will increase substantially to the extent we:
• Our commercial revenues, if any, will be derived from sales of drugs that we do not expect to be commercially available for many years, if ever.

Aligos Therapeutics' latest quarter

Questions

What does Aligos Therapeutics expect?

We expect our research and development expenses to increase substantially in connection with our ongoing and planned clinical development activities for pevifoscorvir sodium and our other drug candidates. As a result, we are unable to determine the duration and completion costs of our research and development projects or clinical trials or if and to what extent we will generate revenue from the commercialization and sale of any of our drug candidates. We expect research and development expenses will increase in future periods as we continue to focus on advancing clinical trials for pevifoscorv

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.